Equity Profile
Pre-Earnings Brief
Arcus Biosciences is a biotechnology company focused on developing innovative cancer therapies. Operating in the health care sector, it aims to address significant unmet medical needs in oncology, which is a major area of investment and research in the biotech industry.
EPS
Earnings per share is a key indicator of profitability and financial health, helping investors gauge the company's performance.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
88%
Avg EPS Surprise
+28.27%
Avg Stock Reaction
-0.37%
In Q4 2025, Arcus reported an EPS of $-0.89, which was better than analysts' expectations of $-1.11, resulting in a positive stock reaction. However, revenue details were not disclosed, leaving some uncertainty about overall financial performance.
Management Promises & Guidance
Analysts expect a loss of $0.83 per share and revenue of $29 million for Q1 2026. Given the company's history of beating EPS estimates, there is cautious optimism among investors.
Bull Case
If Arcus can exceed the EPS estimate and show strong revenue growth, it could signal improving operational efficiency and market acceptance of its therapies, potentially driving the stock higher.
Bear Case
Conversely, if the company fails to meet EPS expectations or shows weak revenue, it could raise concerns about its financial stability and future growth prospects, leading to a significant drop in stock price.
EPS
$-0.83Earnings per share is a key indicator of profitability and financial health, helping investors gauge the company's performance.
Revenue
$29MRevenue figures provide insight into the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will the EPS come in better than the consensus estimate of $-0.83?
A beat on EPS could signal improving operational performance and investor confidence, impacting stock price positively.
Q2
What is the revenue figure compared to the expected $29 million?
Revenue performance is crucial for assessing market demand and the company's growth trajectory, which could influence future investment.
Edge
Why consensus could be wrong
The Street may underestimate Arcus's potential for a significant revenue surprise due to recent advancements in its pipeline that have not been fully factored into estimates.
Supporting Evidence
The company has a history of exceeding EPS estimates, with an 88% beat rate over the last eight quarters.
Recent advancements in their clinical trials could lead to unexpected revenue growth that analysts are not accounting for.
Key Risk
If revenue comes in above $29 million, it could challenge the current bearish sentiment and shift market expectations.
Edge
Pre-commit to what would confirm each case.
The market is debating whether Arcus can maintain its trend of beating EPS estimates while also delivering solid revenue growth.
Bull Confirmed If
An EPS of better than $-0.65 and revenue exceeding $55 million would confirm a strong bull case.
Bear Confirmed If
An EPS worse than $-1.01 and revenue below $7 million would confirm a bearish outlook.
Pre-Earnings Positioning
Implied Move
±4.2%
Historical Avg
±3.1%
The options market is pricing in a potential move of around 4.2% in either direction following the earnings report.
Options are pricing ±12.2% while RCUS has averaged ±3.1% over the last 8 prints — setup is pricing rich.
30d HV
61.3%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Arcus beats expectations, history suggests the stock could rise by about 0.88%, confirming a positive trend in operational performance.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.
Miss
A miss on earnings could lead to a drop of around 9.17%, reflecting investor disappointment and concerns about future growth.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOEWS CORP